Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.54
+0.41 (1.94%)
Mar 17, 2026, 9:30 AM EDT - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$120
Profits / Employee
-$914,827
Market Cap
502.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | 190 | - | - | 188 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Entrada Therapeutics | 152 |
| Invivyd | 122 |
| Verastem | 102 |
| Neumora Therapeutics | 95 |
| enGene Holdings | 82 |
| Prothena Corporation | 67 |
| Lexeo Therapeutics | 61 |
LYEL News
- 4 days ago - Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - GlobeNewsWire
- 8 days ago - Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - GlobeNewsWire
- 10 days ago - Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 22 days ago - Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data - Seeking Alpha
- 3 months ago - Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire